Korro Bio

KRRO on Nasdaq. Pharmaceutical preparations. Market value $187m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-38.2%low

For every $100 of what the whole company costs, it produced $-38.21 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 20 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$12.18 a share, 134% above its 1-year low

Over the past year the price has ranged from $5.20 to $17.35.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
2021202220232024202512 monthsto Sep '26
Revenue
$14m$0$0$2m$6m
Operating margin
-597.3%n/an/a-4047.1%-1906.4%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.04bn0.04bn0.01bn0.01bn0.01bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsShrinking, 29.6% a year
  • Buying back its own sharesYes, 61% fewer since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $0 last quarter, down 100% on a year ago.
  • A loss of $18 million, compared with a loss of $18 million a year ago.
  • It loses 8467 cents on each $1 of sales, compared with 1282 cents a year earlier.
  • Over the past 12 months it spent $64 million more cash than it brought in, compared with $70 million a year earlier.
  • 90% more shares than a year ago. Each share owns a bit less of the company.
  • Sales did not grow on a year ago in any of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$2m
March 2025$3m
June 2025$1m
September 2025$1m
December 2025$1m
March 2026$0
June 2026$0
September 2026$0
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$21m
March 2025-$23m
June 2025-$26m
September 2025-$18m
December 2025-$50m
March 2026-$20m
June 2026-$19m
September 2026-$18m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
12 March 2026
Next quarterly (estimated, 10-Q)
4 February 2027

Who owns it

None of the long-term investors we follow own it. 107 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

10 investors own more than 5%.

  • at least 10.7%+2.9 pts
    (filed with 1 related holder)
    Since 31 March 2026
  • Venrock Healthcare Capital Partners III, L.P.
    Passive investor
    at least 9.9%0.0 pts
    (filed with 6 related holders)
    Since 30 September 2026
  • New Enterprise Associates 17, L.P.
    Passive investor
    at least 9.9%
    (filed with 11 related holders)
    Since 10 March 2026
    What they said

    NEA 17 acquired the NEA 17 Shares for investment purposes. Information with respect to the 2026 Private Placement set forth in Item 3 above is incorporated herein by reference to the extent responsive to this Item 4. Subject to the Registration Rights Agreement, the 2024…

    Read the filing
  • Adage Capital Management, L.P.
    Passive investor
    at least 6.8%
    (filed with 2 related holders)
    Since 30 September 2026
  • at least 6.4%
    (filed with 2 related holders)
    Since 31 December 2025
  • at least 5.9%−0.7 pts
    (filed with 4 related holders)
    Since 30 September 2026
  • Atlas Venture Fund XI, L.P.
    Passive investor
    at least 4.9%
    (filed with 5 related holders)
    Since 24 June 2026
  • Citadel Advisors LLC
    Passive investor
    at least 3.9%
    (filed with 6 related holders)
    Since 31 December 2024
  • Deep Track Capital, LP
    Passive investor
    at least 3.0%
    (filed with 2 related holders)
    Since 30 June 2025
  • Point72 Biotech Private Investments, LLC
    Passive investor
    at least 1.9%−3.8 pts
    (filed with 5 related holders)
    Since 31 March 2026
  • BlackRock, Inc.
    Passive investor
    Sold down below 5%
    Since 30 September 2026
  • FMR LLC
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • AllianceBernstein L.P.
    Passive investor
    Sold down below 5%
    Since 30 June 2025
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026
  • Sold down below 5%
    Since 31 December 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 6 sold $7m, $6m of it under preset trading plans.

  • FORMELA JEAN FRANCOIS
    Director
    Sold
    under a preset trading plan
    Date
    12 November 2026
    Shares
    40,045
    Price
    $14.30
    Value
    $572,644
  • FORMELA JEAN FRANCOIS
    Director
    Sold
    under a preset trading plan
    Date
    11 November 2026
    Shares
    26,587
    Price
    $15.08
    Value
    $400,966
  • FORMELA JEAN FRANCOIS
    Director
    Sold
    under a preset trading plan
    Date
    14 September 2026
    Shares
    38,490
    Price
    $14.12
    Value
    $543,479
  • FORMELA JEAN FRANCOIS
    Director
    Sold
    under a preset trading plan
    Date
    11 September 2026
    Shares
    10,200
    Price
    $13.99
    Value
    $142,698
  • Dolan Oliver
    Senior Vice President, Finance
    Sold
    under a preset trading plan
    Date
    11 September 2026
    Shares
    5
    Price
    $13.72
    Value
    $69
  • Dolan Oliver
    Senior Vice President, Finance
    Sold
    under a preset trading plan
    Date
    9 September 2026
    Shares
    6
    Price
    $13.60
    Value
    $82
  • Dolan Oliver
    Senior Vice President, Finance
    Sold
    under a preset trading plan
    Date
    8 September 2026
    Shares
    7,347
    Price
    $13.51
    Value
    $99,286
  • FORMELA JEAN FRANCOIS
    Director
    Sold
    under a preset trading plan
    Date
    26 August 2026
    Shares
    300
    Price
    $13.96
    Value
    $4,188
  • FORMELA JEAN FRANCOIS
    Director
    Sold
    under a preset trading plan
    Date
    19 August 2026
    Shares
    28,468
    Price
    $14.00
    Value
    $398,552
  • FORMELA JEAN FRANCOIS
    Director
    Sold
    under a preset trading plan
    Date
    11 August 2026
    Shares
    2,143
    Price
    $13.96
    Value
    $29,916

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 5 Nov 2026 and 8 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • Sales have shrunk: 29.6% a year.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.